Cue Biopharma, Inc. (CUE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US22978P1066
Cue Biopharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 27.47 m USD |
| Operating income | -26.55 m USD |
| EBIT | -26.00 m USD |
| Net income | -26.60 m USD |
| Diluted EPS – continuing operations | -0.28 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
More stocks
- Mercuries Data Systems Ltd (2427.TW)
- Young Poong Precision Corporation (036560.KQ)
- Atlas Salt Inc (SALT.V)
- Baby Bunting Group Ltd (BBN.AX)
- Arlen SA (ARL.WA)
- ABC Taiwan Electronics (3236.TWO)
- Sukgyung AT Co. Ltd. (357550.KQ)
- Eagle Cold Storage Enterprise Co Ltd (8905.TWO)
- YoungQin International Co (2755.TWO)
- Nightingale Health Oyj B (HEALTH.HE)
- Gordon Auto Body Parts Co Ltd (1524.TW)
- AirBoss of America Corp. (BOS.TO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.